<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Terpos, E.</style></author><author><style face="normal" font="default" size="100%">Niesvizky, R.</style></author><author><style face="normal" font="default" size="100%">Palumbo, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical characteristics of patients with relapsed multiple myeloma q</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Treatment Reviews</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Immunomodulatory drug</style></keyword><keyword><style  face="normal" font="default" size="100%">multiple myeloma</style></keyword><keyword><style  face="normal" font="default" size="100%">proteasome inhibitor</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84958860945&amp;doi=10.1016%2fj.ctrv.2015.07.005&amp;partnerID=40&amp;md5=e17a362da157a327952035229f9d356e</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">41</style></volume><pages><style face="normal" font="default" size="100%">827 - 835</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Although survival outcomes have improved over the last decade for patients with multiple myeloma (MM), few patients remain free of disease and most inevitably relapse. Selecting a treatment for patients with relapsed MM is challenging given the number and diversity of regimens patients may have previously received, which can affect subsequent therapeutic choices. Importantly, a number of patient- and disease-related factors can also have an effect on treatment choice, treatment efficacy, and tolerability; thus, an understanding of the heterogeneity of patients in the setting of relapsed MM is important for appropriate treatment selection. Here, we review select patient and disease characteristics reported in key interventional and observational studies in relapsed MM (including age, sex, race, and the presence of high-risk disease, renal impairment, or peripheral neuropathy at baseline) to examine common and disparate features of patients with relapsed MM. As therapeutic regimens can have varying efficacy and/or tolerability in patients depending on these factors, we also provide treatment recommendations for patients with select baseline characteristics. © 2015 The Authors.</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue><notes><style face="normal" font="default" size="100%">Cited By :3Export Date: 21 February 2017</style></notes></record></records></xml>